Health ❯ Healthcare ❯ Chronic Conditions

Obesity

Weight Management Treatment Options Type 2 Diabetes Health Risks Weight Loss Medications Diabetes Management Strategies Weight Loss Treatments Weight Regain Cardiovascular Health GLP-1 Medications Treatment Strategies Hypertension Weight Loss Solutions Weight-Related Health Issues Long-term Treatment Wegovy Comorbidities BMI Criteria Autoimmune Diseases Weight Loss Predictors Body Mass Index (BMI) Medication Innovations BMI Heart Failure with Preserved Ejection Fraction Patient Adherence Medications for Weight Loss Health Outcomes GLP-1 Drugs Long-term Treatment Effects GLP-1 Treatment Dementia Medication Management Weight Loss Drugs Public Health Policy Osteoarthritis Related Health Issues Metabolic Disorders Associated Health Risks Medication Effects Obesity Management Weight-Related Comorbidities Migraine Lifestyle Changes Weight Loss Injections Economic Impact Weight Loss Strategies Associated Risks Market Trends BMI and Health Conditions Chronic Lung Disease Hypertension Relationship BMI Monitoring

GLP-1 Drugs Reshape Obesity Care

High prices, patchy insurance, temporary policy fixes limit patient access to GLP-1 medicines.

Secret‑Shopper Study Finds Online GLP‑1 Sellers Quickly Approve Prescriptions With Little Clinician Oversight

Medicare Launches GLP‑1 Bridge to Offer Select Weight‑Loss Drugs for $50 a Month

Study Finds GLP‑1 Diabetes Drugs Linked to Fewer Deaths and Limb Procedures in People With PAD

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

GLP‑1 Agonists Linked to Lower Clot Risk and Mortality in People With Obesity and Autoimmune Disease

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Liraglutide Cuts Chronic Migraine Days by More Than Half